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Therapeutic Advances in Psychopharmacology
Clozapine is an atypical antipsychotic medication 
indicated for the treatment of patients who fail to 
respond to standard antipsychotic treatment. It 
possesses immunomodulatory properties and 
requires regular counts of white blood cells and 
absolute neutrophils. It has been reported to 
mediate several effects on humoral immunity, 
such as altering the levels of antibody-producing 
cytokines [Hinze-Selch et al. 1998].
Selective immunoglobulin M immunodeficiency 
(SIgMD) is a rare form of dysgammaglobulinae-
mia characterized by a selective, low level of 
immunoglobulin M (IgM) in conjunction with 
normal T cell numbers and function, and with no 
other identifiable immunodeficiencies. It can 
occur as either a primary or secondary condition 
and displays an estimated prevalence of 0.03%–
3%. Secondary SIgMD can be associated with 
malignancy, autoimmune disorders, gastrointesti-
nal diseases and/or immunosuppressive treat-
ments [Goldstein et al. 2006].
Here, we present a post hoc analisys based on 
data from a small case-control study designed to 
analyse the presence of SIgMD among clozapine-
treated patients.
This case-control study took place among a 
cohort of psychiatric outpatients referred to the 
Mental Health Unit of the Hospital Real de 
Nuestra Señora de Gracia in Zaragoza, Spain. 
These patients underwent continuous psychiat-
ric, immunological and biochemical monitoring 
over a 5-year follow-up period (2009–2013). The 
case group (n = 8) consisted of all psychiatric 
outpatients who displayed selective SIgMD and a 
control group (n = 92) consisting of randomly 
selected psychiatric outpatients matched to the 
cases on characteristics of age, sex, weight, mental 
health unit, diagnosis and psychiatric medication, 
and who had not displayed selective SIgMD 
(Table 1) [Lozano et al. 2015].
SIgMD was defined by mean IgM values ⩽20mg/dl 
(laboratory reference range of 40–230 mg/dl) 
maintained across the whole follow-up period 
and in conjunction with normal levels of immu-
noglobulin (Ig) A, IgG, white blood cell count 
and absolute neutrophil count. IgM measure-
ments were performed every 6 months and the 
data were averaged for each subject [Lozano et al. 
2015].
We determined plasma immunoglobulin M levels 
in all patients included in study and control 
groups. The study group was constituted of psy-
chiatric outpatients who took clozapine for at 
least 5 years  and, finally, we compared these 
patients with 67 psychiatric outpatients taking 
antipsychotics other than clozapine (control 
group). Student’s t test was used to compare con-
tinuous variables and Fisher’s exact test for com-
paring categorical variables (Table 1). We found 
an increased frequency of SIgMD among psychi-
atric clozapine-treated patients [5 clozapine-
treated patients (14 %) vs 0 No-clozapine-treated 
patients (0%); 95% CI of difference= 0.0355-
0.32677; p = 0.0032]. with an overall decrease of 
mean plasma levels of IgM in the study group 
compared to control group. No differences 
between groups with respect to IgA, IgG, abso-
lute neutrophil count and white blood cell count 
were observed.
Whether this is due to an unknown pharmaco-
logical effect of clozapine or if, alternatively, these 
individuals are part of a subset of psychiatric 
patients who respond differently to antipsychotic 
drugs and/or display a different subpathology or 
endophenotype will require complementary 
studies.
However, our results suggest that healthcare pro-
fessionals must be vigilant with regard to the pres-
ence of SIgMD and/or decrease of IgM plasma 
levels among clozapine-treated patients. The 
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patients affected by SIgMD and/or decrease of 
IgM plasma levels require careful monitoring for 
infection and/or autoimmune diseases. Indeed, 
acute/chronic recurrent rhinosinusitis and allergic 
diathesis of the upper respiratory tract (e.g. hay 
fever, allergic rhinitis, bronchial asthma or atopic 
dermatitis allergies) are frequently observed in 
these patients and may require preventive and/or 
curative therapy.
A potential confounding factor relates to some 
similar genetic abnormalities that are associated 
with both SIgMD and/or decrease of IgM plasma 
levels and schizophrenia (the most frequent diag-
nosis among cases and controls). Indeed, deletion 
of chromosomal region 22q11.2 has been linked 
to some cases of SIgMD and/or decrease of IgM 
plasma levels, and microdeletions occurring in 
this same chromosomal region have been reported 
to result in a 20–30 fold increase in the risk for 
schizophrenia. Although studies have suggested 
differential rates of 22q11.2 deletion syndrome in 
schizophrenia, the reported prevalence ranges 
from 0.5% to 2% (averaging approximately 1%) 
[Horowitz et al. 2005]. Therefore, genetic dele-
tion of 22q11.2 cannot fully account for the sig-
nificantly increased rate of SIgMD and/or 
decrease of IgM plasma levels we observed among 
the clozapine-treated patients.
Regarding the pathogenesis of this disorder, sev-
eral mechanisms have been proposed as causing 
decrease of IgM plasma levels, including 
enhanced regulatory T-cell function, defective T 
helper cells and impaired B lymphocyte differen-
tiation [Yel et al. 2009]. Notably, clozapine 
appears to disregulate both type 1 [e.g. interleu-
kin (IL) 2: subchronic treatment with clozapine 
increasing sIL-2R levels] and type 2 (e.g. IL-10 
and IL-6) cytokines. However, the IL2Rα and β 
genes are localized in the 22q11.2-q12 chromo-
some region, the deletion of which causes 
Table 1. Characteristics of patients in each group.
Variable Cases n = 8 control group (NO 
clozapine-treated) n = 67
p value
Anthropometric
Male sex, no. of patients (%) 13 (38) 27 (41) 1.00
Age, years 44 ± 10 47 ± 14 0.27
Height, cm 175 ± 31 167 ± 21 0.13
Weight, kg 99 ± 21 81 ± 18 <0.01
Body mass index, kg/m2 31 ± 6 29 ± 6 0.12
Diagnosis (DSM-IV)
 Schizophrenia 19 (58) 40 (60) 1.00
 Bipolar disorder 8 (24) 16 (24) 1.00
 Major depressive disorder 1 (3) 2 (3) 1.00
 Other psychotic disorders 5 (15) 9 (13) 1.00
Psychiatric drug treatment
 Antidepressants 12 (36) 20 (30) 0.65
 Antipsychotics (other than clozapine) 0 (0) 67 (100) <0.01
 Clozapine 33 (100) 0 (0) <0.01
 Benzodiazepines 13 (39) 27 (40) 1.00
 Lithium 5 (15) 9 (13) 1.00
Results
 IgA level, mg/dl 189 ± 100 221 ± 131 0.22
 IgG level, mg/dl 1,009 ± 269 1,005 ± 216 0.94
 IgM level, mg/dl 79 ± 59 114 ± 69 0.014
 White blood cell count, cells/μl 7,862 ± 2,593 8.027 ± 2,798 0.74
 Absolute neutrophil count, cells/μl 4,762 ± 1.962 4.607 ± 2,027 0.72
Student’s t test was used to compare continuous variables and Fisher’s exact test for comparing categorical variables.
Mean ± standard deviation; numbers in brackets are percentages.
DSM-IV, Diagnostic and Statistical Manual of Mental Disorders IV; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, 
immunoglobulin M.
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DiGeorge syndrome. Despite all these data, the 
aetiology of this disorder, which is characterized 
by recurrent infections and autoimmunity, 
remains unclear [Kluge et al. 2009].
We acknowledge that our findings might not be 
applicable to all psychiatric clozapine-treated 
patients, as the present study was based on a 
small sample. Therefore, future investigations 
examining larger cohorts and stratifying patient 
study groups according to psychiatric medica-
tion and other major confounding factors (e.g. 
psychiatric diagnoses, deletion of and microdele-
tions in chromosomal region 22q11.2) will be 
required to validate this report. Nevertheless, 
our results indicate that clinicians should pay 
special attention to patterns of IgM decline and 
granulocyte counts among clozapine-treated 
patients.
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